Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

Summary Background Despite widespread use, questions remain about the efficacy of oseltamivir in the treatment of influenza. We aimed to do an individual patient data meta-analysis for all clinical trials comparing oseltamivir with placebo for treatment of seasonal influenza in adults regarding symp...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) 2015-05, Vol.385 (9979), p.1729-1737
Main Authors:	Dobson, Joanna, MSc, Whitley, Richard J, Prof, Pocock, Stuart, Prof, Monto, Arnold S, Prof
Format:	Article
Language:	eng
Subjects:	Adult Adults Aged Antibiotics Antiviral Agents - therapeutic use Double-Blind Method Drug dosages Drug therapy Humans Influenza Influenza, Human - drug therapy Internal Medicine Meta-analysis Middle Aged Oseltamivir - therapeutic use Randomized Controlled Trials as Topic Systematic review Time Factors Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Background Despite widespread use, questions remain about the efficacy of oseltamivir in the treatment of influenza. We aimed to do an individual patient data meta-analysis for all clinical trials comparing oseltamivir with placebo for treatment of seasonal influenza in adults regarding symptom alleviation, complications, and safety. Methods We included all published and unpublished Roche-sponsored randomised placebo-controlled, double-blind trials of 75 mg twice a day oseltamivir in adults. Trials of oseltamivir for treatment of naturally occurring influenza-like illness in adults reporting at least one of the study outcomes were eligible. We also searched Medline, PubMed, Embase, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov trials register for other relevant trials published before Jan 1, 2014 (search last updated on Nov 27, 2014). We analysed intention-to-treat infected, intention-to-treat, and safety populations. The primary outcome was time to alleviation of all symptoms analysed with accelerated failure time methods. We used risk ratios and Mantel-Haenszel methods to work out complications, admittances to hospital, and safety outcomes. Findings We included data from nine trials including 4328 patients. In the intention-to-treat infected population, we noted a 21% shorter time to alleviation of all symptoms for oseltamivir versus placebo recipients (time ratio 0·79, 95% CI 0·74–0·85; p
ISSN:	0140-6736 1474-547X